Semaglutide vs Tirzepatide: Incretin Agonist Comparison
Résumé
Semaglutide and Tirzepatide are the two dominant approved molecules in incretin-based therapy for obesity and type 2 diabetes. Semaglutide (Ozempic/Wegovy) is a mono GLP-1 agonist, while Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1/GIP agonist. Clinical trials show a weight loss advantage for Tirzepatide, but Semaglutide has longer clinical experience.
Propriétés de la substance
What is Semaglutide?
Semaglutide is a selective mono GLP-1 (Glucagon-Like Peptide-1) receptor agonist. Approved as Ozempic (T2D, 2017), Wegovy (obesity, 2021), and Rybelsus (oral), it was the first molecule to record >15% mean weight loss in clinical trials. It reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion.
What is Tirzepatide?
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide) receptor agonist. Approved in 2022 for T2D and 2023 for obesity. The addition of GIP agonism enhances lipolysis and improves glycemic regulation beyond mono GLP-1 agonism.
Mechanism of action: Mono vs Dual agonism
Semaglutide exclusively activates GLP-1R, reducing food intake, increasing satiety, and improving glycemic control. Tirzepatide additionally activates GIPR, which appears to enhance lipolysis, improve fat regulation, and contribute to greater weight loss in clinical trials.
Clinical data: Semaglutide
The STEP trials (obesity) recorded 14.9–16.9% mean weight loss at 68 weeks (2.4 mg). SUSTAIN trials (T2D) showed significant HbA1c reduction. SELECT confirmed a 20% reduction in cardiovascular events. Semaglutide has the longest clinical experience among GLP-1 agonists.
Clinical data: Tirzepatide
The SURMOUNT trials (obesity) recorded 20.9–22.5% mean weight loss at 72 weeks (15 mg). SURPASS-2 (head-to-head vs Semaglutide 1 mg) showed Tirzepatide superiority in HbA1c and weight reduction. Cardiovascular safety studies are ongoing.
Head-to-head: SURPASS-2
In the only published head-to-head trial (SURPASS-2), Tirzepatide 15 mg achieved greater HbA1c reduction (−2.30% vs −1.86%) and weight loss (−12.4 kg vs −6.2 kg) compared to Semaglutide 1 mg over 40 weeks. Important caveat: the Semaglutide dose (1 mg) was the T2D dose, not the maximum obesity dose (2.4 mg).
Safety profile & Side effects
Both show primarily gastrointestinal side effects (nausea 20–35%, diarrhea, constipation) that decrease with gradual titration. Tirzepatide shows slightly higher rates of decreased appetite. Both carry a boxed warning for thyroid C-cell tumors (rodent data). Clinical experience is longer for Semaglutide.
Dosing framework
Semaglutide: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg (titration every 4 weeks). Tirzepatide: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (titration every 4 weeks). Gradual escalation reduces gastrointestinal symptoms.
Guides associés
Foire aux questions (FAQ)
What is the main difference?
Semaglutide is a mono GLP-1 agonist; Tirzepatide is a dual GLP-1/GIP agonist. Tirzepatide shows greater weight loss in trials to date.
Which is more effective?
Tirzepatide shows greater weight loss in clinical trials, but the only head-to-head trial did not use the maximum Semaglutide dose.
Are both approved?
Yes. Both have FDA approval for T2D and chronic weight management.
Références & études
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340.
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
Avertissement
This article is exclusively educational for researchers. It does not constitute medical advice.
⚠️ À des fins informatives et éducatives uniquement. Ne constitue pas un avis médical. Nous ne vendons aucun produit. Avertissement